Knight Therapeutics Stock Investor Sentiment

KHTRF Stock  USD 3.73  0.07  1.84%   
Roughly 62% of Knight Therapeutics' investor base is looking to short. The analysis of overall sentiment of trading Knight Therapeutics pink sheet suggests that many investors are alarmed at this time. The current market sentiment, together with Knight Therapeutics' historical and current headlines, can help investors time the market. In addition, many technical investors use Knight Therapeutics stock news signals to limit their universe of possible portfolio assets.
Knight Therapeutics pink sheet news, alerts, and headlines are usually related to its technical, predictive, social, and fundamental indicators. It can reflect on the current distribution of Knight daily returns and investor perception about the current price of Knight Therapeutics as well as its diversification or hedging effects on your existing portfolios.
  
over a week ago at news.google.com         
Knight Therapeutics Rating Increased to Moderate Buy at Raymond James - MarketBeat
Google News at Macroaxis
over two weeks ago at news.google.com         
Stocks In Play Knight Therapeutics Inc. - Barchart
Google News at Macroaxis
over two weeks ago at news.google.com         
Knight Therapeutics Reports Third Quarter 2024 - Yahoo Finance
Google News at Macroaxis
over three weeks ago at news.google.com         
Notice of Knight Therapeutics Third Quarter 2024 Results Conference Call - Yahoo Finance
Google News at Macroaxis
over a month ago at news.google.com         
Knight Therapeutics Announces Approval of Minjuvi in Mexico - Yahoo Finance
Google News at Macroaxis
over three months ago at news.google.com         
Research Analysts Issue Forecasts for Knight Therapeutics Inc.s FY2024 Earnings - Defense World
Google News at Macroaxis
over three months ago at news.google.com         
Knight Therapeutics Inc. Senior Officer Sells C28,750.00 in Stock - MarketBeat
Google News at Macroaxis
over three months ago at news.google.com         
Knight Therapeutics upgraded to Buy from Accumulate at Stifel - TipRanks
Google News at Macroaxis
over three months ago at news.google.com         
Knight Therapeutics Inc. Just Missed Earnings Heres What Analysts Are Forecasting Now - Yahoo Financ...
Google News at Macroaxis
over three months ago at news.google.com         
Knight Therapeutics Reports Second Quarter 2024 - GlobeNewswire
Google News at Macroaxis
over three months ago at news.google.com         
3 Top Canadian Pharmaceutical Stocks in July 2024 - Stocktrades.ca
Google News at Macroaxis
over three months ago at news.google.com         
GUDCT Stock Price, Quote News - BNN Bloomberg
Google News at Macroaxis
over three months ago at news.google.com         
Knight Therapeutics Inc. Senior Officer Sells C57,000.00 in Stock - American Banking and Market News
Google News at Macroaxis
over three months ago at news.google.com         
Knight Therapeutics Inc. Senior Officer Amal Khouri Sells 10,000 Shares of Stock - Defense World
Google News at Macroaxis
over three months ago at news.google.com         
Knight Announces Normal Course Issuer Bid - Financial Post
Google News at Macroaxis
Far too much social signal, news, headlines, and media speculation about Knight Therapeutics that are available to investors today. That information is available publicly through Knight media outlets and privately through word of mouth or via Knight internal channels. However, regardless of the origin, that massive amount of Knight data is challenging to quantify into actionable patterns, especially for investors that are not very sophisticated with ever-evolving tools and techniques used in the investment management field.
A primary focus of Knight Therapeutics news analysis is to determine if its current price reflects all relevant headlines and social signals impacting the current market conditions. A news analyst typically looks at the history of Knight Therapeutics relative headlines and hype rather than examining external drivers such as technical or fundamental data. It is believed that price action tends to repeat itself due to investors' collective, patterned thinking related to Knight Therapeutics' headlines and news coverage data. This data is often completely overlooked or insufficiently analyzed for actionable insights to drive Knight Therapeutics alpha.

Knight Therapeutics Performance against Dow Jones

 Price Growth (%)  
       Timeline  

Complementary Tools for Knight Pink Sheet analysis

When running Knight Therapeutics' price analysis, check to measure Knight Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Knight Therapeutics is operating at the current time. Most of Knight Therapeutics' value examination focuses on studying past and present price action to predict the probability of Knight Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Knight Therapeutics' price. Additionally, you may evaluate how the addition of Knight Therapeutics to your portfolios can decrease your overall portfolio volatility.
Global Markets Map
Get a quick overview of global market snapshot using zoomable world map. Drill down to check world indexes
Sectors
List of equity sectors categorizing publicly traded companies based on their primary business activities
Equity Forecasting
Use basic forecasting models to generate price predictions and determine price momentum
Analyst Advice
Analyst recommendations and target price estimates broken down by several categories
Correlation Analysis
Reduce portfolio risk simply by holding instruments which are not perfectly correlated
Content Syndication
Quickly integrate customizable finance content to your own investment portal
Portfolio Backtesting
Avoid under-diversification and over-optimization by backtesting your portfolios
Portfolio Suggestion
Get suggestions outside of your existing asset allocation including your own model portfolios
Equity Analysis
Research over 250,000 global equities including funds, stocks and ETFs to find investment opportunities